Gamma-linolenic Acid (GLA): Omega-6 Fatty Acid for LTB4 Receptor Inhibition and Inflammation Research

Executive Summary: Gamma-linolenic acid (GLA; 6Z,9Z,12Z-octadecatrienoic acid) is an omega-6 polyunsaturated fatty acid essential for human health, acting as a weak Leukotriene B4 (LTB4) receptor antagonist (Ki ≈ 1 μM) and suppressing pro-inflammatory signaling in vitro and in vivo [APExBIO]. GLA exhibits antioxidant and anti-mutagenic properties in human HL60 cells at IC50 = 0.087 mM, and inhibits LTB4-induced bronchoconstriction by 53% at 1 mg/kg in animal models [Feng et al., 2025]. Clinically, GLA is effective and well-tolerated in atopic dermatitis and distal diabetic polyneuropathy. APExBIO’s C5518 GLA solution (≥98% purity) is supplied in ethanol and enables robust, reproducible anti-inflammatory research workflows.

Biological Rationale

Gamma-linolenic acid (GLA) is an 18-carbon omega-6 polyunsaturated fatty acid (PUFA) with three cis double bonds at positions 6, 9, and 12. As an essential fatty acid, it must be acquired from dietary sources. PUFAs are categorized as omega-3 or omega-6 based on the position of the first double bond from the methyl end [Feng et al., 2025]. GLA serves as a metabolic precursor to dihomo-γ-linolenic acid (DGLA), which can be further metabolized into anti-inflammatory eicosanoids. In immune tissues, GLA and related PUFAs modulate cellular signaling, membrane fluidity, and inflammatory mediator synthesis. Recent studies have highlighted the immunomodulatory potential of omega-6 fatty acids in augmenting humoral responses [Feng et al., 2025]. Unlike arachidonic acid, GLA is not directly pro-inflammatory; instead, it antagonizes LTB4 receptor signaling, reducing neutrophil recruitment and inflammatory cell activation.

Mechanism of Action of Gamma-linolenic acid (GLA)

GLA acts as a weak antagonist of the LTB4 receptor (BLT1), blocking [3H]-LTB4 binding to neutrophil membranes with a Ki of approximately 1 μM [APExBIO]. This antagonism suppresses the recruitment and activation of inflammatory cells such as neutrophils, monocytes, and eosinophils. By inhibiting LTB4 signaling, GLA modulates downstream pro-inflammatory cytokine production and cell adhesion molecule expression. GLA also exhibits antioxidant and anti-mutagenic properties: it reduces DNA damage and suppresses mutagenicity in promyelocytic HL60 cells at an IC50 of 0.087 mM. These effects are independent of its metabolic conversion and are attributed to its polyunsaturated structure, which scavenges reactive oxygen species (ROS). In animal models, GLA inhibits LTB4-induced bronchoconstriction by 53% at a dose of 1 mg/kg, demonstrating both molecular- and systems-level anti-inflammatory activity.

Evidence & Benchmarks

• GLA inhibits [3H]-LTB4 binding to neutrophil membranes with a Ki of ~1 μM, demonstrating weak but specific LTB4 receptor antagonism (APExBIO).
• In vitro, GLA reduces DNA damage and exhibits anti-mutagenic effects in HL60 promyelocytic cells with an IC50 of 0.087 mM (APExBIO).
• GLA produces 53% inhibition of LTB4-induced bronchoconstriction in vivo at 1 mg/kg (APExBIO).
• GLA is effective and well-tolerated in clinical studies for atopic dermatitis and distal diabetic polyneuropathy (Feng et al., 2025).
• Dietary omega-6 fatty acids, including GLA, enhance humoral immunity via conversion to anti-inflammatory eicosanoids and modulation of B cell activation (Feng et al., 2025).
• GLA solution is stable for short-term use at -20°C and is soluble up to 100 mg/ml in DMSO or DMF; shipped on blue ice (APExBIO).

For further mechanistic context, see 'Gamma-linolenic Acid (GLA): Mechanistic Benchmarks for Anti-Inflammatory Research', which details benchmarking in cytotoxicity assays. This article extends those findings by providing updated quantitative data and clinical context.

Applications, Limits & Misconceptions

GLA is widely used in research on inflammation, lipid metabolism, and immune signaling pathways. It is a validated tool for in vitro and in vivo studies of LTB4 receptor antagonism, apoptosis, and oxidative stress modulation.

• Applications:
• Modeling inflammatory diseases, including atopic dermatitis and distal diabetic polyneuropathy.
• Screening for anti-inflammatory and cytoprotective compounds.
• Benchmarking LTB4 receptor inhibition and oxidative stress mitigation.
• Studying immune cell recruitment, cytokine production, and cell viability.
• Limits:
• GLA is a weak, not potent, LTB4 antagonist; it is not suitable where full receptor blockade is required.
• Its effects are dose- and context-dependent, with high concentrations possibly inducing cytotoxicity.
• GLA is not a direct substitute for potent anti-inflammatory drugs or immunosuppressants.
• Short-term storage and handling are required to maintain stability; long-term exposure to air or light may degrade efficacy.

Common Pitfalls or Misconceptions

• Assuming GLA is a potent LTB4 antagonist—GLA displays only weak antagonism (Ki ≈ 1 μM), not full blockade.
• Expecting GLA to replace pharmaceutical anti-inflammatories—GLA is a research tool, not a clinical replacement for corticosteroids or NSAIDs.
• Overlooking solvent compatibility—GLA is supplied in ethanol and is soluble up to 100 mg/ml in DMSO or DMF; improper solvents reduce activity.
• Neglecting storage guidelines—GLA degrades if not stored at -20°C and protected from light; instability can confound results.
• Assuming universal applicability—GLA’s efficacy depends on cell type, concentration, and experimental context; not all models benefit equally.

For protocol guidance and troubleshooting, see 'Gamma-linolenic acid (GLA, SKU C5518): Data-Driven Solutions for Cytotoxicity Assays'. This article complements that resource by focusing on anti-inflammatory endpoints and LTB4 pathway specificity.

Workflow Integration & Parameters

APExBIO’s gamma-linolenic acid (GLA, SKU C5518) is provided as a solution in ethanol (purity ≥98%, MW = 278.4 g/mol). Recommended storage is at -20°C. It is compatible with DMSO and DMF (solubility up to 100 mg/ml). For cell-based assays, typical working concentrations range from 10 μM to 100 μM for LTB4 antagonism, and up to 0.1 mM for cytotoxicity or antioxidant testing. GLA is shipped on blue ice to maintain stability. It is ideal for short-term use; aliquoting is advised to avoid repeated freeze-thaw cycles.

For a comparative perspective on workflow integration, see 'Gamma-linolenic Acid: Applied Workflows for LTB4 Receptor Antagonism'. This article extends previous workflow guides by emphasizing quantitative benchmarks and clinical translation.

Conclusion & Outlook

Gamma-linolenic acid (GLA) is a validated omega-6 polyunsaturated fatty acid and weak LTB4 receptor antagonist with reproducible anti-inflammatory, anti-mutagenic, and cytotoxic properties. Its role in modulating leukotriene and cytokine signaling has been quantitatively benchmarked in both in vitro and in vivo models. APExBIO’s GLA (C5518) solution offers high purity, convenient formulation, and robust performance in research workflows targeting inflammation and immune modulation. Future studies may further delineate GLA’s efficacy in combinatorial therapies and disease prevention models.